Melissa Badamo

Articles by Melissa Badamo

Melissa BadamoMyeloma | December 9, 2023
The results suggest a possible treatment strategy of selinexor followed by immunotherapy.
Read More
Melissa BadamoMyeloproliferative Neoplasms | December 9, 2023
Tasquinimod inhibited interaction of A9, a protein associated with poor prognosis.
Melissa BadamoMyeloma | December 9, 2023
The survey examined global access to 14 chemoimmunotherapy options and autologous stem cell transplant (ASCT).
Melissa BadamoMyeloproliferative Neoplasms | December 9, 2023
DT2216 alone was effective, but exhibited a slightly greater cell viability reduction when combined with other therapies.
Melissa BadamoMantle Cell Lymphoma | December 6, 2023
Those high-risk disease features include high proliferation index, TP53 mutation, blastoid morphology, and CNS lymphoma.
Melissa BadamoAcute Myeloid Leukemia | December 6, 2023
The study tested the combination therapy in a patient-derived xenograft (PDX) model of NPM1-mutated AML.
Melissa BadamoAggressive B-Cell Lymphoma | December 5, 2023
One-time liso-cel infusion demonstrated durable responses in R/R LBCL.
Melissa BadamoChronic Lymphocytic Leukemia | December 5, 2023
The accelerated approval was based on efficacy results from the BRUIN trial.
Melissa BadamoIndolent B-Cell Lymphoma | December 4, 2023
Researchers assessed the number of patients who received subsequent treatment after tirabrutinib discontinuation.
Melissa BadamoAcute Lymphoblastic Leukemia | December 4, 2023
The study determined the maximum tolerated dose of asciminib with dasatinib and prednisone.
Melissa BadamoAcute Lymphoblastic Leukemia | December 4, 2023
93% of patients became measurable residual disease (MRD) negative after the first cycle of blinatumomab.
Melissa BadamoMyelofibrosis | November 30, 2023
Led by Dr. Lindsay Rein, the goal of the phase I/II trial was to evaluate the safety and efficacy of TP-3654.
Melissa BadamoMyelofibrosis | December 1, 2023
The multicenter trial studied genetic mutations across three cohorts.
Melissa BadamoPolycythemia Vera | November 28, 2023
CR rates were comparable in both treatment groups, but OS was superior in the ruxolitinib group.
Melissa BadamoMyelodysplastic Syndromes | November 27, 2023
The study determined the maximum tolerated dose of CPX-351, but further studies are needed to evaluate its activity.
Melissa BadamoMyelodysplastic Syndromes | November 27, 2023
The study evaluated mesenchymal cell molecular features and sought modifications that might affect MDS.
Melissa BadamoMyelofibrosis | November 17, 2023
Researchers also observed potential disease modification via rapid stabilization of platelets and stable hemoglobin levels.
Melissa BadamoMyelofibrosis | November 16, 2023
The trial is based on “compelling data” from arm III of the ongoing phase II MANIFEST study.
Melissa BadamoMyeloma | November 15, 2023
Of the 200 APPs surveyed, 72% reported being “generally knowledgeable” about MM before seeing their first patient.
Melissa BadamoAcute Myeloid Leukemia | November 14, 2023
Early deaths remain a barrier against understanding a cure-for-all.